Innovus Pharmaceuticals Inc. (fka INNV)

[John Kent]

FlutiCare™ is the first and only nationally branded OTC product under approved ANDA No. 207957 in the U.S. market. FlutiCare™, which is equivalent to Flonase® by GlaxoSmithKline and ClariSpray® by Bayer, is the third national brand being marketed and sold in the U.S. Innovus Pharma will be launching the 120-spray version through its Beyond Human® sales and marketing platform, through other online channels, directly to its over two million e-mail subscribers, and through select retail stores.

FlutiCare™ (fluticasone propionate nasal spray USP, 50 mcg per spray) is indicated for the temporary relief of hay fever and other upper respiratory allergies in adult and pediatric patients 4 years of age and older.

"Having an approved ANDA drug in our product portfolio in a very large indication and being one of only three national brands in the U.S. is a great and long awaited achievement for Innovus Pharma," said Dr. Bassam Damaj, President and Chief Executive Officer of the Company. “We are putting significant efforts into the launch of FlutiCare™ in the U.S. in the second half of this year through our Beyond Human® sales and marketing platform, our other on-line channels, and select retail store sales channels.”

The Company currently expects between $10-15 million in additional revenue from the sales of FlutiCare™ in the U.S. in the first full 12 months from the launch date.

http://www.businesswire.com/news/home/20170509005390/en/Innovus-Pharma-Announces-Commercial-Partnership-Launch-FlutiCare™